 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Syros Pharmaceuticals
SYRS
conference date: March 2, 2023 @ 5:30 AM Pacific Time
Syros Pharmaceuticals A Buy on Price, Pipeline Potential [January 15, 2023 at Seeking Alpha]
Syros Pharmaceuticals Is A Buy As New Trials Start [November 19, 2021 at Seeking Alpha]
Syros Pharmaceuticals After the Orsenix Deal [December 29, 2020 at Seeking Alpha]
| 2023 | |||
| Syros Pharmaceuticals Q4 2022 |
|||
| March 2, 2023 | |||
| 2022 | |||
| Syros Pharmaceuticals Q4 2021 |
Syros Pharmaceuticals Q1 2022 |
Syros Pharmaceuticals Q2 2022 |
Syros Pharmaceuticals Q3 2022 |
| March 15, 2022 | May 16, 2022 | Aug. 9, 2022 | Nov. 14, 2022 |
| 2021 | |||
| Syros Pharmaceuticals Q4 2020 |
Syros Pharmaceuticals Q1 2021 |
Syros Pharmaceuticals Q2 2021 |
Syros Pharmaceuticals Q3 2021 |
| March 4, 2021 | May 6, 2021 | Aug. 5, 2021 | Nov. 5, 2021 |
| 2020 | |||
| Syros Pharmaceuticals Q4 2019 |
Syros Pharmaceuticals Q1 2020 |
Syros Pharmaceuticals Q2 2020 |
Syros Pharmaceuticals Q3 2020 |
| March 5, 2020 | May 7, 2020 | Aug. 6, 2020 | Nov. 5, 2020 |
Syros Pharmaceuticals Update: Still a Buy [January 23, 2020 at Seeking Alpha]
Syros Pharmaceuticals Platform Undervalued [April 10, 2019 at Seeking Alpha]
Syros Pharmaceuticals (SYRS) is a clinical-stage biotechnology company with a platform based on gene regulation.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CLDX |
| CDTX |
| GILD |
| GLYC |
| INCY |
| INO |
| IONS |
| ISRG |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SAGE |
| SGEN |
| VRTX |
| VSTM |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2023 William P. Meyers